Table 3. MET screening results and signal distribution pattern (N=1,579)1.
| Focal Heterogeneous, n (%) | Mosaic Heterogeneous, n (%) | Homogenous, n (%) | Total, n (%) | |
|---|---|---|---|---|
| All | 36 (2.3) | 64 (4.0) | 1,479 (93.7) | 1,579 (100.0) |
| Regions | ||||
| Asia | 11 (4.0) | 6 (2.2) | 259 (93.8) | 276 (100.0) |
| Europe/Australia | 23 (2.0) | 55 (4.8) | 1,064 (93.2) | 1,142 (100.0) |
| North America | 2 (1.3) | 2 (1.3) | 150 (97.4) | 154 (100.0) |
| South America | 0 (0.0) | 1 (14.3) | 6 (85.7) | 7 (100.0) |
| Sex | ||||
| Male | 25 (2.2) | 45 (4.0) | 1,061 (93.8) | 1,131 (100.0) |
| Female | 11 (2.5) | 19 (4.2) | 418 (93.3) | 448 (100.0) |
| Tumor site | ||||
| Gastric | 19 (1.9) | 41 (4.2) | 920 (93.9) | 980 (100.0) |
| GEJ | 3 (1.8) | 5 (3.0) | 161 (95.3) | 169 (100.0) |
| Esophageal | 7 (3.0) | 12 (5.2) | 214 (91.8) | 233 (100.0) |
| Metastatic | 7 (3.5) | 7 (3.5) | 184 (93.0) | 198 (100.0) |
1Data on signal distribution was missing for one patient. MET, mesenchymal epithelial transition factor gene; GEJ, gastroesophageal junction.